Loading...
CytomX Therapeutics, Inc.
CTMX•NASDAQ
Healthcare
Biotechnology
$2.35
$0.16(7.31%)
CytomX Therapeutics, Inc. (CTMX) Financial Performance & Income Statement Overview
Review CytomX Therapeutics, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
36.45%
↑ 36.45%
Operating Income Growth
485.49%
↑ 485.49%
Net Income Growth
5700.88%
↑ 5700.88%
Operating Cash Flow Growth
-53.89%
↓ 53.89%
Operating Margin
24.37%
↑ 24.37%
Gross Margin
64.90%
↑ 64.90%
Net Profit Margin
28.19%
↑ 28.19%
ROE
-553.12%
↓ 553.12%
ROIC
74.46%
↑ 74.46%
CytomX Therapeutics, Inc. (CTMX) Income Statement & Financial Overview
Review CytomX Therapeutics, Inc.'s (CTMX) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $38.09M | $33.43M | $25.11M | $41.46M |
| Cost of Revenue | $413000.00 | $0.00 | $459000.00 | $467000.00 |
| Gross Profit | $37.68M | $33.43M | $24.66M | $41.00M |
| Gross Profit Ratio | $0.99 | $1.00 | $0.98 | $0.99 |
| R&D Expenses | $14.79M | $21.37M | $24.75M | $21.62M |
| SG&A Expenses | $5.62M | $7.95M | $8.36M | $7.72M |
| Operating Expenses | $20.41M | $29.32M | $33.11M | $29.34M |
| Total Costs & Expenses | $20.41M | $29.32M | $33.57M | $29.81M |
| Interest Income | $1.28M | $1.69M | $1.97M | $2.19M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $413000.00 | $429000.00 | $459000.00 | $467000.00 |
| EBITDA | $18.09M | $4.54M | -$8.45M | $12.12M |
| EBITDA Ratio | $0.47 | $0.14 | -$0.34 | $0.29 |
| Operating Income | $17.68M | $4.11M | -$8.45M | $11.66M |
| Operating Income Ratio | $0.46 | $0.12 | -$0.34 | $0.28 |
| Other Income/Expenses (Net) | $1.26M | $1.69M | $1.97M | $2.18M |
| Income Before Tax | $18.94M | $5.80M | -$6.48M | $13.84M |
| Income Before Tax Ratio | $0.50 | $0.17 | -$0.26 | $0.33 |
| Income Tax Expense | $62000.00 | $61000.00 | $51000.00 | $49000.00 |
| Net Income | $18.88M | $5.74M | -$6.53M | $13.79M |
| Net Income Ratio | $0.50 | $0.17 | -$0.26 | $0.33 |
| EPS | $0.22 | $0.07 | -$0.08 | $0.17 |
| Diluted EPS | $0.22 | $0.07 | -$0.08 | $0.17 |
| Weighted Avg Shares Outstanding | $80.10M | $85.09M | $84.88M | $82.03M |
| Weighted Avg Shares Outstanding (Diluted) | $80.10M | $85.20M | $84.88M | $82.63M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan